


## Development of novel Antibody-based assays

OBS offers strategic partnership programs for the development of novel antibody-based assays. The partnerships are milestone driven and enable the development of novel antibody-based assays in, typically, less than a 12 month period.

Using our experience at OBS we can develop novel assays in a range of applications in Drug Development and Diagnostic programs including:

- Monitoring Pharmacodynamic markers
- Monitoring drug efficacy markers
- Monitoring drug toxicity
- Developing novel Diagnostic assays



A key to the ability of OBS to go from discovery to an antibody-based assay in a short duration is the use of our proprietary DECIDER database. The database has been developed over the last 10 years and contains the world's largest proprietary source of protein biomarker information from human biological samples. This enables us to go from a list of candidate biomarkers to a high confidence subset of high-probability biomarkers. This, in turn, significantly reduces the scale of biomarker validation experiments which saves time and resources.

### Phase 1– Biomarker Discovery

OBS uses novel sample fractionation techniques to discover low abundance protein biomarkers

OBS uses highly sensitive techniques for biomarker discovery and protein ID that includes:

LC-MS comparative peptide profiling, 8 plex iTRAQ and 2D Gel Electrophoresis (with MS/MS protein ID)

Univariate and multi-variate statistical analysis to determine significant markers

DECIDER biomarker prioritisation to select specific biomarkers for further assay development

### Phase 2– Biomarker Validation

OBS will use additional samples and highly sensitive techniques to validate biomarkers including:

MRM based approaches for validation and absolute quantitation using triple quadrupole MS

This ensures markers are robust before entering Phase 3– Antibody-based assay development

### Phase 3– Antibody-based Assay Development

OBS will source commercial antibodies to validated biomarkers

Single or Multiple analyte assays will then be developed

Validation of the test can be performed using either EIA, IHC or Western Blot

**For further information on our services please contact:**

Oxford Biomarker Services  
94A Milton Park  
Abingdon, OX14 4RY  
United Kingdom  
T: +44 (0) 1235 861 770  
F: +44 (0) 1235 861 771

Email: [info@biomarkerservices.com](mailto:info@biomarkerservices.com)  
[www.BiomarkerServices.com](http://www.BiomarkerServices.com)

